Literature DB >> 10065336

Endothelins in health and disease: an overview.

R G Goldie1.   

Abstract

1. There is an ever increasing volume of evidence implicating endothelin-1 and its isoforms in a range of disease processes. These include asthma, pulmonary and essential systemic hypertension, cardiac failure and uterine dysfunction. 2. However, it is also important to realize that the endothelins play an obligatory role in normal cellular proliferation, repair and tissue development. 3. The present brief review focuses on some of the physiological and pathophysiological mediator roles of the endothelins and provides a sketch of the receptor systems and some of the signal transduction pathways that are now known to operate following receptor activation. 4. Importantly, it is now clear that the endothelins, their receptors and synthesis and degradation pathways offer potentially important therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10065336     DOI: 10.1046/j.1440-1681.1999.03014.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  18 in total

1.  The polycationic aminoglycosides modulate the vasoconstrictive effects of endothelin: relevance to cerebral vasospasm.

Authors:  G Wickman; M A Nessim; D A Cook; B Vollrath
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

2.  Antivascular therapy for multidrug-resistant ovarian tumors by macitentan, a dual endothelin receptor antagonist.

Authors:  Sun-Jin Kim; Jang Seong Kim; Seung Wook Kim; Seok Joong Yun; Junqin He; Emily Brantley; Dominic Fan; Panja Strickner; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Transl Oncol       Date:  2012-02-01       Impact factor: 4.243

Review 3.  Role of the endothelin axis and its antagonists in the treatment of cancer.

Authors:  A Bagnato; M Loizidou; B R Pflug; J Curwen; J Growcott
Journal:  Br J Pharmacol       Date:  2011-05       Impact factor: 8.739

4.  Endothelin receptor antagonists: rationale, clinical development, and role in prostate cancer therapeutics.

Authors:  Snehal G Thakkar; Toni K Choueiri; Jorge A Garcia
Journal:  Curr Oncol Rep       Date:  2006-03       Impact factor: 5.075

5.  Developmental changes in the functional, biochemical and molecular properties of rat bladder endothelin receptors.

Authors:  Parviz Afiatpour; Jamshid Latifpour; Wataru Takahashi; Makoto Yono; Harris E Foster; Kazuyoshi Ikeda; Mehdi Pouresmail; Robert M Weiss
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-04-17       Impact factor: 3.000

6.  Analysis of correlations between selected endothelial cell activation markers, disease activity, and nailfold capillaroscopy microvascular changes in systemic lupus erythematosus patients.

Authors:  Mariusz Ciołkiewicz; Anna Kuryliszyn-Moskal; Piotr Adrian Klimiuk
Journal:  Clin Rheumatol       Date:  2009-11-12       Impact factor: 2.980

7.  A phase I study of zibotentan (ZD4054) in patients with metastatic, castrate-resistant prostate cancer.

Authors:  William R Schelman; Glenn Liu; George Wilding; Thomas Morris; De Phung; Robert Dreicer
Journal:  Invest New Drugs       Date:  2009-09-19       Impact factor: 3.850

Review 8.  Angiogenesis inhibition in the treatment of prostate cancer.

Authors:  Ravi A Madan; William L Dahut
Journal:  Anticancer Agents Med Chem       Date:  2009-12       Impact factor: 2.505

Review 9.  Endothelin-1 as a target for therapeutic intervention in prostate cancer.

Authors:  E Scott Kopetz; Joel B Nelson; Michael A Carducci
Journal:  Invest New Drugs       Date:  2002-05       Impact factor: 3.850

Review 10.  ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer.

Authors:  Ruth Warren; Glenn Liu
Journal:  Expert Opin Investig Drugs       Date:  2008-08       Impact factor: 6.206

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.